Moderna (MRNA) shares ripped higher on Friday as reports of a planned U.S. initiative to accelerate cancer vaccine development renewed enthusiasm for its oncology business. According to The New York Times, the proposed public-private partnership would bring together federal researchers, drugmakers, nonprofits and patients, with a launch expected in December.
Moderna stock has been nothing short of a blockbuster investment in 2026, currently trading at about 7x its price at the start of this year.